Physician profile
Li Wei Chang
NPI 1215468178
$1,057.21
in general payments reported to CMS, 2019-2025
14 companies · $21.50 in 2025
The $21.50 reported for 2025 was less than what a typical Mohs-Micrographic Surgery provider received nationally (typical 2025 total: $462).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $364 · 2021: $19.20 · 2023: $315 · 2024: $338 · 2025: $21.50.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $659 · Education: $15.96.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $658.52 |
| Education | $15.96 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $508.59 | 2019-2024 | Skyrizi |
| Stemline Therapeutics INC. | $103.28 | 2019 | |
| Ortho Dermatologics, A Division of Bausch Health US, LLC | $69.53 | 2023-2024 | Siliq |
| Boehringer Ingelheim Pharmaceuticals, INC. | $51.25 | 2023-2024 | Spevigo |
| Incyte Corporation | $50.08 | 2023-2024 | Opzelura |
| Ucb, INC. | $47.77 | 2023 | Bimzelx, Cimzia |
| Lilly USA, LLC | $47.18 | 2023-2024 | Taltz, Olumiant |
| Regeneron Pharmaceuticals, INC. | $45.00 | 2019 | |
| Regeneron Healthcare Solutions, INC. | $44.94 | 2024 | Dupixent, Libtayo |
| Leo Pharma INC. | $24.88 | 2023 | Adbry |
| Biofrontera INC. | $21.50 | 2025 | Ameluz |
| Fresenius Kabi USA, LLC | $15.33 | 2023 | Idacio |
| Blueprint Medicines Corporation | $14.65 | 2023 | |
| Janssen Biotech, INC. | $13.23 | 2023 | Simponi Aria, Simponi, Stelara |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Li Wei Chang listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.